Skip to main content

Table 2 Extracellular vesicle-based therapeutics for pulmonary fibrosis models

From: Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics

Donor cells Mouse models EV delivery Recipient cells EV components Ref
BM-MSCs BLM i.v Alveolar macrophages Unknown (modulation of monocyte phenotypes) [50]
BM-MSCs BLM i.v Lung fibroblasts miR-29b-3p [51]
BM-MSCs BLM i.v Lung fibroblasts miR-186 [52]
UC-MSCs BLM i.v Alveolar epithelial cells, lung fibroblasts miR-21-5p and -23-3p [53]
UC-MSCs silica i.v Lung fibroblasts Unknown [54]
Endometrial stem cells BLM i.v Alveolar epithelial cells let-7 [55]
Engineered dermal fibroblasts BLM i.t Alveolar macrophages, lung fibroblasts, vascular endothelial cells miRNAs with anti-inflammatory and anti-fibrotic functions [56]
Bronchial epithelial cells BLM i.t Lung fibroblasts, alveolar epithelial cells miR-16, miR-26a, miR-26b, miR-141, miR-148a, and miR-200a [10]
Lung spheroid cells BLM/silica i.h Unknown miR-30a, miR-99a, miR-100, and let-7 [11]
  1. BM-MSCs bone marrow mesenchymal stem cells, UC-MSCs umbilical cord mesenchymal stem cells, BLM bleomycin, i.v intravenous, i.t intratracheal, i.h inhalation